Search by Drug Name or NDC
NDC 00002-5337-54 Verzenio 150 mg/1 Details
Verzenio 150 mg/1
Verzenio is a ORAL TABLET in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Eli Lilly and Company. The primary component is ABEMACICLIB.
MedlinePlus Drug Summary
Abemaciclib is used in combination with an aromatase inhibitor such as anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) to treat a certain type of hormone receptor-positive, early breast cancer. Abemaciclib is also used along with fulvestrant (Faslodex) to treat a certain type of hormone receptor-positive, advanced breast cancer (breast cancer that depends on hormones such as estrogen to grow) or breast cancer that has spread to other parts of the body after treatment with an antiestrogen medication such as tamoxifen. Abemaciclib is also used along with anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) as a first treatment of hormone receptor-positive, advanced breast cancer or breast cancer that has spread to other parts of the body. Abemaciclib is also used alone to treat a certain type of hormone receptor-positive, advanced breast cancer or breast cancer that has spread to other parts of the body in people who have already been treated with an antiestrogen medication and chemotherapy. Abemaciclib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells.
Related Packages: 00002-5337-54Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Abemaciclib
Product Information
| NDC | 00002-5337 |
|---|---|
| Product ID | 0002-5337_1bfe414d-380c-400b-8ae2-7caa0877dcad |
| Associated GPIs | 21531010000315 |
| GCN Sequence Number | 077777 |
| GCN Sequence Number Description | abemaciclib TABLET 150 MG ORAL |
| HIC3 | V1Q |
| HIC3 Description | ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS |
| GCN | 43916 |
| HICL Sequence Number | 044537 |
| HICL Sequence Number Description | ABEMACICLIB |
| Brand/Generic | Brand |
| Proprietary Name | Verzenio |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | abemaciclib |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET |
| Route | ORAL |
| Active Ingredient Strength | 150 |
| Active Ingredient Units | mg/1 |
| Substance Name | ABEMACICLIB |
| Labeler Name | Eli Lilly and Company |
| Pharmaceutical Class | Kinase Inhibitor [EPC], Kinase Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | NDA |
| Application Number | NDA208716 |
| Listing Certified Through | 2025-12-31 |
Package
NDC 00002-5337-54 (00002533754)
| NDC Package Code | 0002-5337-54 |
|---|---|
| Billing NDC | 00002533754 |
| Package | 1 BLISTER PACK in 1 CARTON (0002-5337-54) / 14 TABLET in 1 BLISTER PACK |
| Marketing Start Date | 2017-10-06 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |